Clinical Trials — 2010

Andrew D. Badley, M.D.

1. Early Access of MK-0518
2. Cardio-Metabolic Risk Factors in HIV+ [Protocol 1]
3. Kusne/ViroPharma/Maribavir versus Oral Ganciclovir for prevention of Cytomegalovirus Disease
4. The effects of Nelfinavir on Immune Function
5. Maraviroc Used With Optimized Background Therapy (POEM)
6. Laboratory Assay Optimization
7. CXCR4 Mediated Apoptosis of Primary Hepatocytes
8. The Incidence, Clinical Course and Management of Sepsis in the Intensive Care Unit: A Prospective Observational Cohort Study
9. Regulation of HIV-Mediated CD4 Cell Apoptosis

Leslie T. Cooper, M.D.

1. Autoimmune Determinants of Human Cardiac Myosin — This is a mechanistic registry that seeks to enroll 55 patients with acute myocarditis.
2. Peripartum Cardiomyopathy Registry — This is a mechanistic registry that seeks to enroll 100 patients with peripartum cardiomyopathy.

Gregory A. Poland, M.D.

1. Measles — The Immunogenetics of Measles Vaccine.
2. Rubella — The Immunogenetic Mechanisms of Vaccine Response.
3. Smallpox — Population Genetics Analysis Program: Immunity to Vaccines/Infections.
4. Chiron — A Phase II, Single-center, Oberver-blind trial of AGRIPPAL S1/MF59 vs. AGRIPPAL S1 in Elderly Subjects.
5. Novavax —A Phase 2a Randomized, Double Blind Active Controlled Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (recombinant) in Older Adults in the US and India.

Lewis R. Roberts, Ph.D.

1. 09-000096 — GIDEON: Global investigation of therapeutic decision in hepatocellular carcinoma and of its treatment. An International Non-Interventional Study with Nexavar to evaluate the safety in patients with unresectable hepatocellular carcinoma.
2. 707-03 — A National Registry of Patients with or at Risk for Hepatobiliary Cancers, Including Hepatocellular Carcinoma, Cholangiocarcinoma, and Gallbladder Adenocarcinoma, and those with Normal Risk Factors.
3. 08-002048 — A phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and safety of ThermoDox (Thermally Sensitive Liposomal Doxorubicin) in Combination with Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma.